Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy.
Identifieur interne : 000324 ( PubMed/Checkpoint ); précédent : 000323; suivant : 000325Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy.
Auteurs : Eric Russell [États-Unis] ; Francis Luk ; Sonia Manocha ; Tung Ho ; Carolyn O'Connor ; Humaira HussainSource :
- Seminars in arthritis and rheumatism [ 1532-866X ] ; 2013.
Descripteurs français
- KwdFr :
- MESH :
- traitement médicamenteux : Sarcoïdose, Sarcoïdose pulmonaire.
- usage thérapeutique : Anticorps monoclonaux.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Infliximab, Mâle, Reprise du traitement, Résultat thérapeutique, Sujet âgé, Études de suivi.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antibodies, Monoclonal.
- drug therapy : Sarcoidosis, Sarcoidosis, Pulmonary.
- Adult, Aged, Female, Follow-Up Studies, Humans, Infliximab, Male, Middle Aged, Retreatment, Treatment Outcome.
Abstract
Infliximab, a humanized, chimeric, monoclonal antibody against tumor necrosis alpha (TNF-α), has been shown to reduce the pulmonary and extra-pulmonary manifestations of sarcoidosis, however, there is little information regarding sustained efficacy with long-term use of infliximab. We retrospectively investigate whether a reduction in disease response is maintained, over a prolonged course of therapy (up to 85 months) with infliximab, and report on adverse events associated with its use.
DOI: 10.1016/j.semarthrit.2012.10.008
PubMed: 23332903
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:23332903Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy.</title><author><name sortKey="Russell, Eric" sort="Russell, Eric" uniqKey="Russell E" first="Eric" last="Russell">Eric Russell</name><affiliation wicri:level="2"><nlm:affiliation>Christiana Care Rheumatology Department,Wilmington, DE. USA. ERussell@ChristianaCare.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Delaware</region></placeName><wicri:cityArea>Christiana Care Rheumatology Department,Wilmington</wicri:cityArea></affiliation></author><author><name sortKey="Luk, Francis" sort="Luk, Francis" uniqKey="Luk F" first="Francis" last="Luk">Francis Luk</name></author><author><name sortKey="Manocha, Sonia" sort="Manocha, Sonia" uniqKey="Manocha S" first="Sonia" last="Manocha">Sonia Manocha</name></author><author><name sortKey="Ho, Tung" sort="Ho, Tung" uniqKey="Ho T" first="Tung" last="Ho">Tung Ho</name></author><author><name sortKey="O Connor, Carolyn" sort="O Connor, Carolyn" uniqKey="O Connor C" first="Carolyn" last="O'Connor">Carolyn O'Connor</name></author><author><name sortKey="Hussain, Humaira" sort="Hussain, Humaira" uniqKey="Hussain H" first="Humaira" last="Hussain">Humaira Hussain</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23332903</idno><idno type="pmid">23332903</idno><idno type="doi">10.1016/j.semarthrit.2012.10.008</idno><idno type="wicri:Area/PubMed/Corpus">000346</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000346</idno><idno type="wicri:Area/PubMed/Curation">000346</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000346</idno><idno type="wicri:Area/PubMed/Checkpoint">000324</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000324</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy.</title><author><name sortKey="Russell, Eric" sort="Russell, Eric" uniqKey="Russell E" first="Eric" last="Russell">Eric Russell</name><affiliation wicri:level="2"><nlm:affiliation>Christiana Care Rheumatology Department,Wilmington, DE. USA. ERussell@ChristianaCare.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Delaware</region></placeName><wicri:cityArea>Christiana Care Rheumatology Department,Wilmington</wicri:cityArea></affiliation></author><author><name sortKey="Luk, Francis" sort="Luk, Francis" uniqKey="Luk F" first="Francis" last="Luk">Francis Luk</name></author><author><name sortKey="Manocha, Sonia" sort="Manocha, Sonia" uniqKey="Manocha S" first="Sonia" last="Manocha">Sonia Manocha</name></author><author><name sortKey="Ho, Tung" sort="Ho, Tung" uniqKey="Ho T" first="Tung" last="Ho">Tung Ho</name></author><author><name sortKey="O Connor, Carolyn" sort="O Connor, Carolyn" uniqKey="O Connor C" first="Carolyn" last="O'Connor">Carolyn O'Connor</name></author><author><name sortKey="Hussain, Humaira" sort="Hussain, Humaira" uniqKey="Hussain H" first="Humaira" last="Hussain">Humaira Hussain</name></author></analytic><series><title level="j">Seminars in arthritis and rheumatism</title><idno type="eISSN">1532-866X</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Infliximab</term><term>Male</term><term>Middle Aged</term><term>Retreatment</term><term>Sarcoidosis (drug therapy)</term><term>Sarcoidosis, Pulmonary (drug therapy)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Infliximab</term><term>Mâle</term><term>Reprise du traitement</term><term>Résultat thérapeutique</term><term>Sarcoïdose (traitement médicamenteux)</term><term>Sarcoïdose pulmonaire (traitement médicamenteux)</term><term>Sujet âgé</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Sarcoidosis</term><term>Sarcoidosis, Pulmonary</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Sarcoïdose</term><term>Sarcoïdose pulmonaire</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Infliximab</term><term>Male</term><term>Middle Aged</term><term>Retreatment</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Infliximab</term><term>Mâle</term><term>Reprise du traitement</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Infliximab, a humanized, chimeric, monoclonal antibody against tumor necrosis alpha (TNF-α), has been shown to reduce the pulmonary and extra-pulmonary manifestations of sarcoidosis, however, there is little information regarding sustained efficacy with long-term use of infliximab. We retrospectively investigate whether a reduction in disease response is maintained, over a prolonged course of therapy (up to 85 months) with infliximab, and report on adverse events associated with its use.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23332903</PMID><DateCompleted><Year>2014</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-866X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Seminars in arthritis and rheumatism</Title><ISOAbbreviation>Semin. Arthritis Rheum.</ISOAbbreviation></Journal><ArticleTitle>Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy.</ArticleTitle><Pagination><MedlinePgn>119-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.semarthrit.2012.10.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0049-0172(12)00265-X</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Infliximab, a humanized, chimeric, monoclonal antibody against tumor necrosis alpha (TNF-α), has been shown to reduce the pulmonary and extra-pulmonary manifestations of sarcoidosis, however, there is little information regarding sustained efficacy with long-term use of infliximab. We retrospectively investigate whether a reduction in disease response is maintained, over a prolonged course of therapy (up to 85 months) with infliximab, and report on adverse events associated with its use.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Subjects with multi-organ sarcoidosis were prescribed infliximab, between January 2000 to June 2010 due to failure of conventional therapy and were identified from the Drexel University College of Medicine sarcoidosis clinic. Retrospective patient reported symptom and objective clinical data analyses of pulmonary and extra-pulmonary findings were evaluated pre-infliximab and post or concurrent infliximab therapy. Any adverse events or reasons for discontinuation during infliximab therapy were reported.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-six patients with biopsy proven sarcoidosis received anti-TNF therapy and met the criteria for study inclusion. Clinical evidence of sustained resolution or improvement was demonstrated in 58.5% of all organs assessed (p =<0.001). No clinical change in disease activity was seen in 35.8% of all organs evaluated. Despite infliximab treatment, 5.7% had progressive disease activity. Adverse events were seen in 57.7% of patients treated with infliximab over a 46.2 month average duration of therapy. Three (12%) patients had an adverse event that required permanent discontinuation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Infliximab is efficacious in the treatment of extra-pulmonary sarcoidosis and the efficacy is maintained with prolonged treatment. In patients with pulmonary sarcoid, sustained improvement in pulmonary imaging was seen after initiation of infliximab, however, post-treatment pulmonary function testing was not conclusive. Long-term infliximab therapy was well tolerated for our study group.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Christiana Care Rheumatology Department,Wilmington, DE. USA. ERussell@ChristianaCare.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luk</LastName><ForeName>Francis</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Manocha</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Tung</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Humaira</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Arthritis Rheum</MedlineTA><NlmUniqueID>1306053</NlmUniqueID><ISSNLinking>0049-0172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>B72HH48FLU</RegistryNumber><NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Semin Arthritis Rheum. 2014 Apr;43(5):e2</RefSource><PMID Version="1">24315124</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012507" MajorTopicYN="N">Sarcoidosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017565" MajorTopicYN="N">Sarcoidosis, Pulmonary</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AE</Keyword><Keyword MajorTopicYN="N">Anti-TNF</Keyword><Keyword MajorTopicYN="N">CNS</Keyword><Keyword MajorTopicYN="N">CT</Keyword><Keyword MajorTopicYN="N">DLCO</Keyword><Keyword MajorTopicYN="N">FEV1</Keyword><Keyword MajorTopicYN="N">FVC</Keyword><Keyword MajorTopicYN="N">HCQ</Keyword><Keyword MajorTopicYN="N">HPV</Keyword><Keyword MajorTopicYN="N">IFX</Keyword><Keyword MajorTopicYN="N">Infliximab</Keyword><Keyword MajorTopicYN="N">LN</Keyword><Keyword MajorTopicYN="N">MRI</Keyword><Keyword MajorTopicYN="N">MTX</Keyword><Keyword MajorTopicYN="N">PFT</Keyword><Keyword MajorTopicYN="N">PPD</Keyword><Keyword MajorTopicYN="N">Remicade</Keyword><Keyword MajorTopicYN="N">Sarcoid</Keyword><Keyword MajorTopicYN="N">Sarcoidosis</Keyword><Keyword MajorTopicYN="N">TLC</Keyword><Keyword MajorTopicYN="N">TNF</Keyword><Keyword MajorTopicYN="N">Tumor necrosis factor inhibitor</Keyword><Keyword MajorTopicYN="N">adverse events</Keyword><Keyword MajorTopicYN="N">carbon monoxide diffusing capacity</Keyword><Keyword MajorTopicYN="N">central nervous system</Keyword><Keyword MajorTopicYN="N">computerized tomography</Keyword><Keyword MajorTopicYN="N">forced expiratory volume in 1s</Keyword><Keyword MajorTopicYN="N">forced vital capacity</Keyword><Keyword MajorTopicYN="N">human papilloma virus</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">infliximab</Keyword><Keyword MajorTopicYN="N">lymph node</Keyword><Keyword MajorTopicYN="N">magnetic resonance imaging</Keyword><Keyword MajorTopicYN="N">methotrexate</Keyword><Keyword MajorTopicYN="N">pulmonary function test</Keyword><Keyword MajorTopicYN="N">purified protein derivative</Keyword><Keyword MajorTopicYN="N">total lung capacity</Keyword><Keyword MajorTopicYN="N">tumor necrosis factor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>06</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23332903</ArticleId><ArticleId IdType="pii">S0049-0172(12)00265-X</ArticleId><ArticleId IdType="doi">10.1016/j.semarthrit.2012.10.008</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Delaware</li></region></list><tree><noCountry><name sortKey="Ho, Tung" sort="Ho, Tung" uniqKey="Ho T" first="Tung" last="Ho">Tung Ho</name><name sortKey="Hussain, Humaira" sort="Hussain, Humaira" uniqKey="Hussain H" first="Humaira" last="Hussain">Humaira Hussain</name><name sortKey="Luk, Francis" sort="Luk, Francis" uniqKey="Luk F" first="Francis" last="Luk">Francis Luk</name><name sortKey="Manocha, Sonia" sort="Manocha, Sonia" uniqKey="Manocha S" first="Sonia" last="Manocha">Sonia Manocha</name><name sortKey="O Connor, Carolyn" sort="O Connor, Carolyn" uniqKey="O Connor C" first="Carolyn" last="O'Connor">Carolyn O'Connor</name></noCountry><country name="États-Unis"><region name="Delaware"><name sortKey="Russell, Eric" sort="Russell, Eric" uniqKey="Russell E" first="Eric" last="Russell">Eric Russell</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000324 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000324 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:23332903
|texte= Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:23332903" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |